Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — SEB Healthcare Seminar (January 2022)
21 slides from Cantargia Ab's conference presentation, Jan 19, 2022
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Göran Forsberg, CEO Jan 2022 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia: the IL1RAP company
Cantargia: the IL1RAP company FIRST IN CLASS ANTIBODY THERAPIES AGAINST NOVEL IL1RAP TARGET • Five Phase I/II trials, with positive interim data in pancreatic cancer and NSCLC • Differentiated by broad MOA and unique binding properties • Synergistic with established therapies PLATFORM WITH BROAD POT
Slide 4: Cantargia – Save lives and create value through IL1RAP
Cantargia – Save lives and create value through IL1RAP Potentially more effective treatment against novel target in clinically validated pathway First in class platform technology against novel target Well financed to build a broad, diversified pipeline Right team and clear plan to position our proj
Slide 5: Advancing PDAC development to phase 2/3
Advancing PDAC development to phase 2/3 PanCAN’s Precision Promise adaptive clinical trial platform designed together with FDA Nadunolimab selected for inclusion → 15 leading US clinical centers - additional sites planned → Patients randomized to receive nadunolimab with gemcitabine and nab-paclitax
Slide 6: Nadunolimab and biological context
NADUNOLIMAB AND BIOLOGICAL CONTEXT
Slide 7: IL1RAP is overexpressed in most solid tumors
IL1RAP is overexpressed in most solid tumors IL1RAP EXPRESSION IN SOLID TUMOR TYPES IL1RAP-EXPRESSING CELLS IN TUMOR MICROENVIRONMENT IL1RAP-expressing tumors 100 75 50 25 0 l C C st al ic er er ta SC CL at ge ea Liv d ec ad re NS HN ha Br r nc lo Bl op Co Pa Es Cancer cell surface Stroma IL1RAP: DI
Slide 8: Nadunolimab – Differentiated and superior MOA
Nadunolimab – Differentiated and superior MOA Company Compound IL-1α IL-1β ADCC Indication/development phase Nadunolimab Nadunolimab Cantargia (CAN04) ++ ++ ++ Pancreatic cancer, NSCLC phase IIa Xbiotech/ Xilonix Autoimmunity, dermatology Janssen XB2001 ++ – + Pancreatic cancer, phase I Autoimmunity
Slide 9: Nadunolimab mechanism uniquely enhances docetaxel antitumor activity
Nadunolimab mechanism uniquely enhances docetaxel antitumor activity ✱ Nadunolimab 100 Nadunolimab with docetaxel in MC38 syngeneic model: Tumor growth (%) → Nadunolimab blocks both IL-1α and IL-1β and has ADCC activity → Nadunolimab increases efficacy of docetaxel 50 → Control antibody blocking onl
Slide 10: Combination strategy in NSCLC – Promising efficacy
Combination strategy in NSCLC – Promising efficacy Nadunolimab combination with Gem/Cis in 1st line chemotherapy: → 13 of 27 evaluable patients with non-sq non-small cell lung cancer (NSCLC) showed objective response including 1 complete response (ORR 48% vs historical control data of 22-28%) → No m
Slide 11: Strong signal in non-squamous NSCLC
Strong signal in non-squamous NSCLC Non-squamous NSCLC 50 Percent tumor reduction Stable disease * * * * * * * * Partial response 0 (RECIST 1.1) Complete response * Post pembrolizumab Ongoing Nadunolimab combination with Gem/Cis in 1st line chemotherapy: -50 → Non-squamous NSCLC comprises approx. 75
Slide 12: Positive interim data in pancreatic cancer
Positive interim data in pancreatic cancer Nadunolimab combination with Gem/Abraxane in 1st line (Dec 2021), n=33: → 27% response rate with durable responses, two patients still on treatment → Pseudoprogression-like response in 5 (15%) patients predict long PFS → Promising PFS (7.2 mo) and OS (12.7
Slide 13: Safety profile is manageable and supports MOA
Safety profile is manageable and supports MOA CANFOUR Gem/Abraxane FOLFIRINOX Nadunolimab/ Grade 3 or higher AEs (von Hoff) (Conroy 2011) Gem/Abraxane N=421 N=171 N=36 Neutropenia 38% 67% 46% → G-CSF is an approved therapy to counteract neutropenia; G-CSF Febrile neutropenia 3% 17% 5% w
Slide 14: Large number of clinical milestones during 2022
Cantargia – Save lives and create value through IL1RAP LARGE NUMBER OF CLINICAL MILESTONES DURING 2022 BASED ON INITIAL RESULTS, MOST PROMISING OPPORTUNITIES TO BE EXPANDED 14
Slide 15: CAN10 opportunity in autoimmune/inflammatory disease
CAN10 OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 16: CAN10 – New asset within autoimmunity/inflammation
CAN10 – New asset within autoimmunity/inflammation → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation) → Development focusing on unmet medical need in syste
Slide 17: CAN10 – Unique properties in preclinical disease models
CAN10 – Unique properties in preclinical disease models Myocarditis - Treatment from day 7 Left Ventricular Ejection Fraction 1.1 ** Ratio of baseline 1.0 * mCAN10 Control mCAN10 0.9 Anti-IL-1β Control Anti-IL-1β 0.8 Vehicle 0.7 0 10 20 30 40 Day Myocarditis - Treatment from day 7 Left Ventricular E
Slide 18: Financials, milestones & summary
FINANCIALS, MILESTONES & SUMMARY
Slide 19: Solid financial position with strong shareholder support
Solid financial position with strong shareholder support → Cash and cash equivalents SEK 647.9 M (~$71M) at end Q3 2021 Current owners (31 Dec 2021) → Operating expenses SEK 264.5 M (~$29M) in Q1-Q3 2021 • R&D is 95% of operating expenses Swedbank Robur Funds 9.6% • 24 full-time employees 4th AP fun
Slide 20: Several upcoming value inflection points
Several upcoming value inflection points Newsflow over next 6-9 months Nadunolimab (CAN04) → New results for PDAC, NSCLC and Keytruda combination → Phase 2/3 Precision Promise (PDAC) → New preclinical and translational results → New clinical trials (Interim results, safety) • CAPAFOUR PDAC FOLFIRINO
Slide 21: Cantargia: the IL1RAP company
Cantargia: the IL1RAP company FIRST IN CLASS ANTIBODY THERAPIES AGAINST NOVEL IL1RAP TARGET • Five Phase I/II trials, with positive interim data in pancreatic cancer and NSCLC • Differentiated by broad MOA and unique binding properties • Synergistic with established therapies PLATFORM WITH BROAD POT